Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer
PET Clinics · 2026
DOI: 10.1016/j.cpet.2025.08.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2026. Verfasst von Kimberly Luddy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunotherapy, Radiopharmaceuticals. Die Arbeit nennt 80 Literaturangaben. Gefördert von: National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
This review highlights the critical role of evolutionary dynamics in metastatic prostate cancer treatment. It emphasizes that resistance arises through Darwinian selection, often driven by continuous maximum tolerated dose therapies. Evolution-informed strategies, such as adaptive therapy and exploiting collateral sensitivities, aim to delay resistance and prolong disease control by steering tumor evolution. Radiopharmaceutical therapy, especially when combined with immunotherapy, offers promising avenues for targeting disseminated tumors. Integrating mathematical models and computer simulations to understand tumor evolution can optimize personalized, adaptive treatment regimens, transforming resistance from a failure into an exploitable vulnerability, ultimately improving outcomes in advanced prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
- Department of Integrated Mathematical Oncology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
- Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.
- Department of Radiology, Cancer Biology and Evolution Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address: Robert.gatenby@moffitt.org.
Förderung
- National Institutes of Health National Cancer Institute
Zitieren
APA
Luddy, K., Newman, H., Gravon, J., Robertson-Tessi, M., & Gatenby, R. (2026). Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clinics. https://doi.org/10.1016/j.cpet.2025.08.006
Vancouver
Luddy K, Newman H, Gravon J, Robertson-Tessi M, Gatenby R. Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clinics. 2026. doi:10.1016/j.cpet.2025.08.006
BibTeX
@article{Luddy2026,
author = {Luddy, Kimberly and Newman, Hannah and Gravon, Jordan and Robertson-Tessi, Mark and Gatenby, Robert},
title = {Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer},
journal = {PET Clinics},
year = {2026},
doi = {10.1016/j.cpet.2025.08.006}
}
EUVIMED